Nanatinostat + Valganciclovir (Nana-val)
Relapsed/Refractory EBV+ Lymphomas (PTCL, CTCL, DLBCL)
Key Facts
About Viracta Therapeutics
Viracta Therapeutics was a precision oncology company developing targeted therapies for Epstein-Barr virus (EBV)-associated cancers, a significant unmet medical need. Its core strategy centered on a proprietary 'lytic induction therapy' platform, which combined a viral activator (nanatinostat) with an antiviral prodrug (valganciclovir) to selectively kill virus-infected cancer cells. The company's lead program, Nana-val, advanced into Phase 2 trials for relapsed/refractory EBV+ lymphomas and a Phase 1b/2 trial for nasopharyngeal carcinoma. Following strategic reviews and financial challenges, Viracta wound down its operations in 2024.
View full company profileAbout Viracta Therapeutics
Viracta Therapeutics was a precision oncology company developing targeted therapies for Epstein-Barr virus (EBV)-associated cancers, a significant unmet medical need. Its core strategy centered on a proprietary 'lytic induction therapy' platform, which combined a viral activator (nanatinostat) with an antiviral prodrug (valganciclovir) to selectively kill virus-infected cancer cells. The company's lead program, Nana-val, advanced into Phase 2 trials for relapsed/refractory EBV+ lymphomas and a Phase 1b/2 trial for nasopharyngeal carcinoma. Following strategic reviews and financial challenges, Viracta wound down its operations in 2024.
View full company profileAbout Viracta Therapeutics
Viracta Therapeutics was a precision oncology company developing targeted therapies for Epstein-Barr virus (EBV)-associated cancers, a significant unmet medical need. Its core strategy centered on a proprietary 'lytic induction therapy' platform, which combined a viral activator (nanatinostat) with an antiviral prodrug (valganciclovir) to selectively kill virus-infected cancer cells. The company's lead program, Nana-val, advanced into Phase 2 trials for relapsed/refractory EBV+ lymphomas and a Phase 1b/2 trial for nasopharyngeal carcinoma. Following strategic reviews and financial challenges, Viracta wound down its operations in 2024.
View full company profile